Editas Medicine (EDIT) Posts Smaller Q2 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Editas Medicine Announces Second Quarter 2020 Results and Update
August 6, 2020 4:06 PM EDTRegained full control of ocular medicines under new agreement with AbbVie
BRILLIANCE trial for EDIT-101 on track to dose at least three patients by end of 2020
Plan to file IND for EDIT-301 for sickle cell disease by end of 2020
Strengthened balance sheet through equity offering raising $216 million in gross proceeds
Cash, cash equivalents, and marketable securities of $599 million as of June 30, 2020
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq:... More
